Drugs / MRKAd5 HIV-1 gag/pol/nef
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00095576 | Nov 2004 → Sep 2007 | AIDS | Merck Sharp & Dohme LLC | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRK AD5 HIV-1 Gag/Pol/Nef | “Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef)” NCT00095576 ↗ |
| Modality | Vaccine | “investigational Human Immunodeficiency Virus (HIV) vaccine” NCT00095576 ↗ |
| Route | Intramuscular | “three 1.0-ml intramuscular (IM) injections” NCT00095576 ↗ |